JP2016515615A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016515615A5 JP2016515615A5 JP2016506281A JP2016506281A JP2016515615A5 JP 2016515615 A5 JP2016515615 A5 JP 2016515615A5 JP 2016506281 A JP2016506281 A JP 2016506281A JP 2016506281 A JP2016506281 A JP 2016506281A JP 2016515615 A5 JP2016515615 A5 JP 2016515615A5
- Authority
- JP
- Japan
- Prior art keywords
- hydroxyl
- composition according
- hydrogen
- alkyl
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 C*(CC=[S@](C)*=O)c1cc(N=O)c(*)cc1 Chemical compound C*(CC=[S@](C)*=O)c1cc(N=O)c(*)cc1 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NZ60910613 | 2013-04-05 | ||
| NZ609106 | 2013-04-05 | ||
| PCT/NZ2014/000059 WO2014163512A1 (en) | 2013-04-05 | 2014-04-07 | Therapeutic compositions comprising extracts of propolis and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016515615A JP2016515615A (ja) | 2016-05-30 |
| JP2016515615A5 true JP2016515615A5 (enExample) | 2017-07-06 |
| JP6444984B2 JP6444984B2 (ja) | 2018-12-26 |
Family
ID=51658695
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016506281A Active JP6444984B2 (ja) | 2013-04-05 | 2014-04-07 | プロポリス抽出物を含む治療組成物およびその使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20160030364A1 (enExample) |
| EP (1) | EP2981254B1 (enExample) |
| JP (1) | JP6444984B2 (enExample) |
| CN (1) | CN105163728B (enExample) |
| AU (1) | AU2014250138B2 (enExample) |
| TW (1) | TW201517901A (enExample) |
| WO (1) | WO2014163512A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014163513A1 (en) | 2013-04-05 | 2014-10-09 | Manuka Health New Zealand Limited | Therapeutic compositions and uses thereof |
| TW201609113A (zh) * | 2014-07-18 | 2016-03-16 | 歐文 約翰 蓋奇波 | 治療組合物及其用途 |
| RU2568876C1 (ru) * | 2015-02-11 | 2015-11-20 | Федеральное государственное бюджетное научное учреждение "Научный центр неврологии" (ФГБНУ НЦН) | Способ определения оксима пиностробина в плазме крови |
| CN109310660B (zh) * | 2016-03-24 | 2023-07-11 | 蜜纽康新西兰有限公司 | 治疗组合物及其用途 |
| CN106913873A (zh) * | 2017-04-26 | 2017-07-04 | 中国药科大学 | 巴西绿蜂胶在制备pdt抗肿瘤的协同增效药物中的应用 |
| WO2020086830A2 (en) * | 2018-10-26 | 2020-04-30 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
| CN109912607B (zh) * | 2018-12-11 | 2021-01-22 | 南华大学 | 一类卟啉-白杨素复合物及其抗肿瘤活性 |
| JP2022547721A (ja) * | 2019-09-17 | 2022-11-15 | エンゼン・バイオサイエンシズ・リミテッド | Ｓｒｃキナーゼの阻害、ならびに関連障害の処置及び予防において使用するための組成物 |
| CN116492324A (zh) * | 2023-01-04 | 2023-07-28 | 河南科技大学第一附属医院 | 咖啡酸在预防和治疗结直肠癌中的应用、含咖啡酸的药物 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| JP2004521880A (ja) * | 2000-12-13 | 2004-07-22 | ユニバ−シティ オブ ロチェスタ− | 口腔組成物及びその使用方法 |
| US6689811B2 (en) * | 2001-04-20 | 2004-02-10 | Wake Forest University | Method of using caffeic acid phenethyl ester and analogs thereof as radiation sensitizers |
| JP2003119169A (ja) * | 2001-07-30 | 2003-04-23 | Shigetoshi Kadota | 細胞毒性活性を有する化合物およびそれを有効成分とする医薬組成物 |
| US7790762B2 (en) * | 2002-10-31 | 2010-09-07 | National Jewish Health | Compounds and methods for thiol-containing compound efflux and cancer treatment |
| KR100968367B1 (ko) * | 2006-10-02 | 2010-07-06 | 재단법인서울대학교산학협력재단 | 카페인산 유도체 및 이를 유효성분으로 포함하는 조성물 |
| CN101502506B (zh) | 2009-02-24 | 2011-08-17 | 连晓媛 | 咖啡酸3,4-二羟基苯乙酯的医药用途 |
| WO2011156889A1 (en) * | 2010-06-14 | 2011-12-22 | Trt Pharma Inc. | Novel modulators of nrf2 and uses thereof |
| CN101875648B (zh) * | 2010-07-12 | 2012-12-12 | 马灵媛 | 一种从药用植物中提取纯化球松素的方法及其药物制剂与应用 |
| WO2013022740A2 (en) * | 2011-08-05 | 2013-02-14 | Corning Incorporated | Gpr35 ligands and the uses thereof |
| WO2013078371A2 (en) * | 2011-11-22 | 2013-05-30 | The Johns Hopkins University | Methods and compositions for reducing alcohol toxicity |
| CN102949384A (zh) * | 2012-10-29 | 2013-03-06 | 浙江大学 | 咖啡酸3，4-二羟基苯乙酯在制备抗肿瘤药物中的应用 |
| CN104016862A (zh) * | 2013-02-28 | 2014-09-03 | 北京大学 | 咖啡酸苯乙酯酚羟基保护衍生物的制备及其作为神经保护剂和抗肿瘤药物的应用 |
| WO2014163513A1 (en) * | 2013-04-05 | 2014-10-09 | Manuka Health New Zealand Limited | Therapeutic compositions and uses thereof |
-
2014
- 2014-04-07 EP EP14779926.6A patent/EP2981254B1/en active Active
- 2014-04-07 JP JP2016506281A patent/JP6444984B2/ja active Active
- 2014-04-07 AU AU2014250138A patent/AU2014250138B2/en active Active
- 2014-04-07 CN CN201480022371.8A patent/CN105163728B/zh active Active
- 2014-04-07 US US14/781,860 patent/US20160030364A1/en not_active Abandoned
- 2014-04-07 WO PCT/NZ2014/000059 patent/WO2014163512A1/en not_active Ceased
- 2014-04-07 TW TW103112675A patent/TW201517901A/zh unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016515615A5 (enExample) | ||
| JP2016516751A5 (enExample) | ||
| Bhuvaneswari et al. | Targeting EGFR with photodynamic therapy in combination with Erbitux enhances in vivo bladder tumor response | |
| JP2015520753A5 (enExample) | ||
| JP2016224056A5 (enExample) | ||
| JP2015500225A5 (enExample) | ||
| JP2009513662A5 (enExample) | ||
| JP2020516646A5 (enExample) | ||
| JP2016522202A5 (enExample) | ||
| JP2012509279A5 (enExample) | ||
| WO2011151722A3 (en) | Methods and compositions for oral pharmaceutical therapy | |
| CY1118486T1 (el) | Λαπατινιμπη για τη θεραπεια του καρκινου | |
| US20120208883A1 (en) | Treatment of oncological diseases | |
| TW201043225A (en) | Antitumour combination comprising AVE8062 and sorafenib | |
| WO2019189772A1 (ja) | 長鎖ノンコーディングｒｎａを標的とするがん治療剤およびがん診断方法 | |
| WO2009067520A3 (en) | Peptides specific for hepatocellular carcinoma cells and applications thereof | |
| WO2011094260A3 (en) | Novel bifunctional metnase/intnase inhibitors and related compositions and methods of treatment of cancer | |
| MX2021015467A (es) | Compuestos y metodos de uso. | |
| US20210145811A1 (en) | Treatment of cancer with exon 14 skipping mutation(s) or exon 14 skipping phenotype | |
| JP2014524479A5 (enExample) | ||
| Osada et al. | Growth inhibition of unresectable tumors induced by hepatic cryoablation: report of two cases | |
| Dearnaley et al. | Escalated-dose Conformai radiotherapy for localised prostate cancer: long-term overall survival results from the MRC RT01 randomised controlled trial | |
| CN109481687B (zh) | 用于胃癌治疗的cdk4/6抑制剂联合her2抑制剂的组合 | |
| JP2018199726A5 (enExample) | ||
| JP2014118361A5 (enExample) |